Letters
Prostate cancer screening
Report bias favours screening
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d3703 (Published 14 June 2011) Cite this as: BMJ 2011;342:d3703
- Maren Dreier, senior researcher in epidemiology1,
- Thorsten Meyer, professor in rehabilitation research1,
- Ulla Walter, professor in public health1
- 1Hanover Medical School (MHH), Institute for Epidemiology, Social Medicine and Health Systems Research, 30625 Hanover, Germany
- dreier.maren{at}mh-hannover.de
While aiming to assess prostate cancer specific mortality, Sandblom and colleagues indicate a “prostate cancer specific mortality” in the screening group of 35% and in the control group of 45%, which actually is the case fatality rate.1 The true prostate cancer specific mortality was 2% (30/1494) in the screening group and 1.7% (130/7532) in …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.